v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets    
Cash and cash equivalents $ 296,113 $ 261,820
Accounts receivable, net 182,140 235,746
Prescription reimbursement assets 1,076,012 98,331
Prepaid expenses and other current assets 45,062 47,205
Total current assets 1,599,327 643,102
Property and equipment, net 11,514 12,268
Goodwill 430,331 430,331
Intangible assets, net 58,254 64,082
Capitalized software, net 140,300 139,261
Operating lease right-of-use assets, net 27,630 28,808
Deferred tax assets, net 47,335 57,111
Other assets 28,237 29,095
Total assets 2,342,928 1,404,058
Current liabilities    
Accounts payable 8,906 19,405
Prescription reimbursement liabilities 1,039,995 130,139
Accrued expenses and other current liabilities 98,610 86,705
Current portion of debt 5,000 5,000
Operating lease liabilities, current 5,358 4,753
Total current liabilities 1,157,869 246,002
Debt, net 481,588 483,264
Operating lease liabilities, net of current portion 47,004 49,789
Other liabilities 8,866 8,741
Total liabilities 1,695,327 787,796
Commitments and contingencies (Note 7)
Stockholders' equity    
Preferred stock, $0.0001 par value; 50,000 shares authorized and nil shares issued and outstanding at June 30, 2026 and December 31, 2025 0 0
Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, 106,164 and 107,088 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively; and Class B: 1,000,000 shares authorized, 233,964 shares issued and outstanding at June 30, 2026 and December 31, 2025 34 34
Additional paid-in capital 2,048,436 2,026,802
Accumulated deficit (1,400,869) (1,410,574)
Total stockholders' equity 647,601 616,262
Total liabilities and stockholders' equity $ 2,342,928 $ 1,404,058